SAG and congestive heart failure: Thus, the ideal ligand profiles for both the ß2AR and AT1 receptor, when used in CHF, appear to be ligands that antagonize the G-protein pathway (Gs and Gq respectively), and either stimulate, or at least not antagonize the receptor conformation that promotes ß-arrestin-dependent signaling.